Barclays analyst Matt Miksic raised the firm’s price target on DexCom to $110 from $103 and keeps an Equal Weight rating on the shares post the Q4 results. The company delivered Q4 sales and a 2023 outlook in-line with its preannouncement, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on DXCM: